Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ148 in pregnant women with primary HCMV infection
2017-002047-15Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in congenital cytomegalovirus infection (cCMV) comparing CSJ148 with Placebo (2 arms). Primary endpoint: Event rate of fetuses or neonates with congenital human cytomegalovirus infection. Started Mar 2018; status: terminated.
02
Drugs
CSJ148
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on 2017-002047-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002047-15.